News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sangamo (SGMO) Announces Second Quarter 2017 Conference Call And Webcast



8/3/2017 12:14:50 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

RICHMOND, Calif., Aug. 2, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its second quarter 2017 financial results after the market closes on Wednesday, August 9, 2017. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.

Sangamo Therapeutics, Inc. (PRNewsFoto/Sangamo BioSciences, Inc.) (PRNewsFoto/)

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 54328579. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors Relations section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 54328579.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-second-quarter-2017-conference-call-and-webcast-300498618.html

SOURCE Sangamo Therapeutics, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES